NewAmsterdam Pharma Co N.V. (NAMS)
↓ Download CSV- Sector Manufacturing
- Incorporated P7
- Fiscal year ends Dec 31
In fiscal 2025, NewAmsterdam Pharma Co N.V. reported revenue of $22.50M, down 50.6% from the prior year. The company ran a net loss, with a net margin of -905.7%. It held $769.28M in total assets against $85.85M in total liabilities.
Key ratios (FY2025)
-1002.9%
Operating margin
-905.7%
Net margin
-29.8%
Return on equity
-50.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $22.50M | $45.56M | $14.09M | $102.69M | — | — |
| Operating Income | -$225.68M | -$176.29M | -$182.97M | -$3.56M | -$34.98M | — |
| Net Income | -$203.82M | -$241.60M | -$176.94M | -$22.63M | -$41.78M | — |
| EPS (Diluted) | $-1.72 | $-2.56 | $-2.15 | $-1.19 | $-3.81 | — |
| Total Assets | $769.28M | $864.62M | $347.10M | $478.50M | — | — |
| Total Liabilities | $85.85M | $107.12M | $58.70M | $48.43M | — | — |
| Shareholders' Equity | $683.43M | $757.50M | $288.39M | $430.07M | -$113.82M | -$73.03M |
| Cash & Equivalents | $490.00M | $771.74M | $340.45M | — | — | — |
| Operating Cash Flow | -$147.78M | -$158.56M | -$141.22M | $10.66M | -$29.51M | — |
| Capital Expenditures | $246.0K | $672.0K | $24.0K | $221.0K | $24.0K | — |
| Shares Outstanding | 118.42M | 94.36M | 82.16M | 18.97M | 10.98M | — |